Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane, Gemcitabine, and Avastin in Metastatic Breast Cancer
NCT00662129Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2008
- Primary completion
- Aug 2010
- Modality
- Polymer-based Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel and bevacizumab in breast cancer, sponsored by Cancer and Leukemia Group B. Primary endpoint: 6-month Progression-free Survival Rate. Started Nov 2008; status: completed.
02
Drugs
nab-paclitaxelbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00662129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662129.